OBJECTIVES: To estimate the expected cost of the pharmacological treatment on prevalence of arterial hypertension (AH), diabetes mellitus (DM) and dyslipidemia in the Chilean population, following the recent approval of Drug National Funds. METHODS: The drugs considered in this study and the information about it, were obtained through a review of clinical guideline or technical norms published by the health ministery of Chile. The cost was estimated using the drug consumption patterns from the national health survey 2009-2010 and from a vector of prices for every drug and their combination of uses, for both public and private health systems through the public market platform and IMS health Chile. 10.000 Montecarlo simulations were performed to propagate the uncertainty of parameters. RESULTS: The expected cost (and its credibility intervals of 95%) of the prevalent population with AH, DM and dyslipidemia using prices from public health system was in Chilean pesos (CLP$) CLP$12,463MM (CLP$11,394MM – CLP$13,622MM), CLP$36,425MM (CLP$25,603MM – CLP$49,624MM) and CLP$20,658MM (CLP$11,090MM – CLP$33,284MM) respectively. While, the estimated cost based on private health system was CLP$700,613MM (CLP$561,764MM – CLP$865,354MM), CLP$333,921MM (CLP$253,963MM – CLP$436,879MM) and CLP$680,919MM (CLP$327,916MM – CLP$1,645,906MM) respectively.  CONCLUSIONS: The expected cost needed for the treatment of the three conditions studied represent 1.3% and 2.9% in the worst case scenario (33% considering private system prices) of the 2014 health budget, and the effort to improve the subdiagnostic of these conditions would determine a budget impact of at least 0.86%, only with pharmacological treatment.